drugset / Trial / NCT06051851
Penpulimab Combined With Anlotinib and Nab-paclitaxel Plus Gemcitabine as First-line Treatment for Advanced Metastatic Pancreatic Cancer
Phase 2
Unknown
177 enrolled
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a multi-center, open-label， randomized controlled Phase II clinical study to observe and evaluate the efficacy and safety of Penpulimab combined with Anlotinib and Nab-paclitaxel plus Gemcitabine (PAAG ) versus AG first-line treatment in patients with metastatic pancreatic cancer.
Timeline
- Start
- 2023-07-01
- Primary completion
- 2025-07-01
- Completion
- 2026-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | 10 mg | Oral |
| Subject | Catequentinib | Small molecule | 12 mg | Oral |
| Subject | Penpulimab | Monoclonal antibody | 200 mg | Intravenous |
| Background | Gemcitabine | Small molecule | 1 g | Intravenous |
| Background | Paclitaxel | Small molecule | 125 mg/m2 | Intravenous |